Lovastatin CAS: 75330-75-5
MF: C24H36O5
MW: 404.54
A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels).

Lovastatin (CAS 75330-75-5)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 128ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
5
0
4
0
3
1
2
0
1
0
Sinonimo: Mevacor;Monacolin K;mevinolin;6-α-Methylcompactin
Applicazione: A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels)
Numero CAS: 75330-75-5
Purezza: ≥97%
Peso molecolare: 404.54
Formula molecolare: C24H36O5
* Vedere Certificato di Analisi per informazioni sul lotto specifico (incluso il contenuto d'acqua).
Invia una review per questo prodotto e ricevi 15 Cruz Credits

Lovastatin is a statin natural product isolated from numerous sources including the Pleurotus ostreatus oyster mushroom, demonstrating hypocholesterolemic and antiproliferative properties. Lovastatin inhibits HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), blocking the enzyme-catalyzed transformation of 3-hydroxy-3-methylglutaryl CoA into mevalonate. The biosynthesis of cholesterol requires mevalonate as a building block and elimination of mevalonate generation subsequently interrupts cholesterol synthesis, leading to a reduction of circulating low-density lipoproteins. Lovastatin demonstrates arrest of the cell cycle at the G1 phase in bladder carcinoma T24 cells expressing activated p21ras oncoprotein - the posttranslational isoprenylation of the p21ras with mevalonate is crucial for translocation and membrane adhesion of the protein, and blockade of this modification by Lovastatin-induced depletion of cellular mevalonate leads to suspension of cell progress. The signaling activity of epidermal growth factor (EGF) and insulin-like growth factor (IGF-I) are similarly affected by impairment of mevalonate-dependent protein prenylation. Induction of apoptosis by Lovastatin in malignant mesothelioma cells is also ascribed to the inhibition of mevalonate synthesis and posttranslational protein modifications. Lovastatin is a substrate of CYP and Mdr-1.


Referenze

1. Alberts, A.W. 1988. Am. J. Cardiol. 62: 10J-15J. PMID: 3055919
2. Hancock, J.F., et al. 1989. Cell. 57: 1167-1177. PMID: 2661017
3. Mendola, C.E. and Backer, J.M. 1990. Cell Growth Differ. 1: 499-502. PMID: 2278880
4. Vincent, T.S., et al. 1991. Biochem. Biophys. Res. Commun. 180: 1284-1289. PMID: 1953779
5. Jakóbisiak, M., et al. 1991. Proc. Natl. Acad. Sci. U.S.A. 88: 3628-3632. PMID: 1673788
6. Rubins, J.B., et al. 1998. Am. J. Respir. Crit. Care Med. 157: 1616-1622. PMID: 9603146
7. Bobek, P., et al. 1998. Nutrition. 14: 282-286. PMID: 9583372
8. Kim, W.S., et al. 2001. Invest New Drugs. 19: 81-83. PMID: 11291836

Stato fisico :
Solid
Derivato da :
Non-native source; synthetic
Solubilità :
Soluble in DMSO (10 mg/ml), ethanol (10 mg/ml), methanol, chloroform, acetone, acetonitrile, DMF, and water (0.4 µg/ml).
CONSERVAZIONE :
Store at -20° C
Punto di scioglimento :
175.4° C
Punto di ebollizione :
~559.2° C at 760 mmHg (Predicted)
Densità :
~1.1 g/cm3 (Predicted)
Indice di rifrazione :
n20D 1.53
Attività ottica :
α20/D 320°±10°, c = 0.5 in CH3CN
IC50 :
HMG-CoA reductase: IC50 = 0.01 µM (rat); Inhibition of the incorporation of sodium [14C]acetate into cholesterol: IC50 = 0.05 µM (HEP G2 cells); inhibition of recombinant ICAM-1 binding to purified immobilized LFA-1: IC50 = 3.78 µM; CYP51: IC50 = 200 µM (human)
Ki Data :
HMG-CoA reductase: Ki= 0.6 nM
Solo per uso in Ricerca. Non previsto per Uso Diagnostico o Terapeutico.
WGK Germania :
3
RTECS :
EK7907000
PubChem CID :
53232
Indice Merck :
14: 5586
Numero MDL :
MFCD00072164

Download SDS (MSDS)

CERTIFICATO DI ANALISI

Adobe Acrobat Reader necessario per una visualizzazione affidabile,
stampa e commenta sui documenti PDF

Lovastatin  Citazioni prodotti

Vedi quanti altri hanno usato Lovastatin. Clicca sulla voce per laccesso a PubMed .

Ciatazioni 1 a7 di 7 totali

PMID: # 27159577  Shimada, K. et al. 2016. Nature chemical biology. 12: 497-503.

PMID: # 26243146  Meunier, S. et al. 2015. Nature communications. 6: 7889.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 9653194  De Petrocellis, L. et al. 1998. Proc. Natl. Acad. Sci. USA. 95: 8375-8380.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

Ciatazioni 1 a7 di 7 totali
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 159ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 10ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

La Santa Cruz Biotechnology, Inc. è un leader mondiale nello sviluppo di prodotti per il mercato della ricerca biomedica. Chiamaci al numero gratuito 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. Tutti i diritti riservati. "Santa Cruz Biotechnology", ed il logo Santa Cruz Biotechnology, Inc."Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", il logo San Juan Ranch, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", ed "EZ Touch" sono marchi registrati dalla Santa Cruz Biotechnology, Inc.
Tutti i marchi sono proprietà dei rispettivi proprietari.